Article
rare donor registries is required to obtain high-prevalence antigen-negative blood for transfusion. Several studies have compared molecular genotyping platforms with serologic phenotyping in patients and donors, with excellent concordance rates.16,19–21
Two PCR-based molecular genotyping platforms commercially available in the United States for blood group genotyping are the human erythrocyte antigen (HEA) PreciseType (formerly HEA BeadChip; Immucor, Norcross, GA) and ID CORE XT (Progenika-Grifols
C.A. Sheppard,
N.L. Bolen,
G. Meny,
M. Kalvelage,
G. Ochoa-Garay
Immunohematology, Volume 36 , ISSUE 4, 123–128
Article
Automated testing platforms facilitate the introduction of red cell genotyping of patients and blood donors. Fluidic microarray systems, such as Luminex XMAP (Austin, TX), are used in many clinical applications, including HLA and HPA typing. The Progenika ID CORE XT (Progenika Biopharma-Grifols, Bizkaia, Spain) uses this platform to analyze 29 polymorphisms determining 37 antigens in 10 blood group systems. Once DNA has been extracted, processing time is approximately 4 hours. The system is
Mindy Goldman,
Núria Nogués,
Lilian M. Castilho
Immunohematology, Volume 31 , ISSUE 2, 62–68